

## Synthesis of Admantane Substituted Spiro 1,2,4-Trioxanes Using Simple and Cheap Starting Material

LALIT KUMAR\*, NIRANJAN KAUSHIK, ANUJ MALIK and PRADEEP KUMAR†  
Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences  
Manipal Academy of Higher Education, Manipal-576 119, India  
E-mail: pradeep\_alpine@yahoo.co.in

Spiro 1,2,4-trioxane are synthetic derivative of artemisinin (1,2,4-trioxane is supposed to be a pharmacophore of artemisinin) which is a well known antimalarial drug from leaves of *Artemisia annua* found in China. Spiro 1,2,4-trioxane substituted with adamantane and its 4 different derivatives were synthesized using well standardized method. These compounds were purified by simple column chromatography and successfully analyzed using <sup>1</sup>H NMR, IR and FAB-MS techniques.

**Key Words:** 1,2,4-Trioxane, Artemisinin, NMR, IR, FAB-MS.

### INTRODUCTION

Malaria is a major parasitic disease, affecting over 100 countries of the tropical and subtropical regions of the world. Around 300-500 million clinical cases of malaria are reported every year, of which more than a million die of severe and complicated cases of malaria<sup>1</sup>. The increasing resistance of causal parasite, *Plasmodium* to the contemporary antimalarial drugs, including chloroquine, has further complicated the malaria problem. Against this scenario, isolation of artemisinin **1** as the antimalarial principle of Chinese traditional herb, *Artemisia annua*, is a major milestone in the history of malaria chemotherapy. Artemisinin is very effective and safe against chloroquine sensitive and chloroquine resistant strains of *P. falciparum*, but has certain limitations like poor oil and water solubility and high rate of recrudescence. Hence a lot of efforts have been put to develop semi synthetic derivatives of artemisinin. Ether derivatives of artemisinin<sup>2-5</sup> have the advantage of better oil solubility and are prepared by treating dihydroartemisinin with an appropriate alcohol in the presence of an acid catalyst. Artemether **2** and arteether **3** (Fig. 1) are the 2 most important derivatives of artemisinin. Both of them show better oil solubility and improved activity and are currently in clinical use.

The antimalarial activity of artemisinin and its clinically useful derivatives such as artemether **2**, arteether **3** and artesunic acid **4** (Fig. 1) is due to the presence of 1,2,4-trioxane moiety in their molecular structure. Because of the limited availability

---

†Department of Pharmaceutical Analysis, PES College of Pharmacy, Bangalore-560 050, India.

of artemisinin, currently the focus is on the synthesis and antimalarial assessment of structurally simplified 1,2,4-trioxanes and a variety of methods of their synthesis has been reported in recent years<sup>6,7</sup>. In contrast, 1,2,4-trioxepanes, the next higher homologs of 1,2,4-trioxanes and the next obvious candidates for structure activity relationship (SAR) studies in this area, have received only limited attention. Only a few methods of their synthesis have been reported<sup>8-12</sup>, the number of compounds synthesized is small.





Fig. 1

A well standardized method by photooxygenation route for the preparation of 1,2,4-trioxepanes has been used for the preparation of 3-(1-phenyl-vinyl)-1,2,5-trioxa-spiro undecane and its 4 derivatives. The key steps of this method are (i) preparation of  $\alpha$ -hydroxyhydroperoxides by photooxygenation of homoallylic alcohols and (ii) acid catalyzed condensation of these hydroxyhydroperoxides with various ketones to furnish 1,2,4-trioxepanes (**Scheme-I**)<sup>9</sup>.




In this article, the preparations of 3-(1-phenyl-vinyl)-1,2,5-trioxa-spiro undecane **5** and its 4 derivatives (**5a-d**) are reported.

## EXPERIMENTAL

**Procedure:** Aromatic ketones **1a-e** were taken, which were subjected to Reformatsky reaction using ethylbromoacetate, zinc and iodine crystals in benzene to furnish  $\beta$ -hydroxy ester, which on dehydration using *p*-toluene sulfonic acid

(pTSA) furnish  $\alpha$ - $\beta$  and  $\beta$ - $\gamma$  isomers of unsaturated esters (**2a-e** and **3a-e**),  $\beta$ - $\gamma$  unsaturated esters were isomerized **3a-e** to  $\alpha$ - $\beta$  unsaturated ester **2a-e**.  $\alpha$ - $\beta$  Unsaturated esters were then reduced using lithium aluminium hydride, to furnish allyl alcohols. These allyl alcohols **4a-e** were then photo-oxygenated using methylene blue, oxygen and visible light furnished respective  $\beta$ -hydroxy-hydroperoxides which were condensed with 2-adamantanone using conc. HCl as catalyst to furnish, after column chromatography over silica gel (60-120 mesh), respective trioxanes **5a-5e**.

**General section:** All apparatus were oven-dried prior to use. The progress of all the reaction was monitored by thin layer chromatography over silica gel coated TLC plates. The spots on TLC plates were developed by the following developing agents: iodine vapours, spraying with an aqueous solution of vanillin in 10 % sulphuric acid followed by heating at 150 °C. Chromatographic purification was performed over Merck and Spectrochem Pvt. Ltd, silica gel (60-120mesh). Infrared



spectra ( $\text{cm}^{-1}$ ) were recorded on Perkin-Elmer FT-IR RX-1 spectrophotometer.  $^1\text{H}$  NMR spectra were recorded on Bruker DPX-200 spectrometers. Tetra methyl silane was used as an internal standard. Chemical shifts are reported in ppm relative to TMS. Coupling constants are reported in Hertz (Hz). Splitting patterns are designated as (s, singlet; bs, broad singlet; d, doublet; t, triplet; q, quadruplet; dd, doublet of doublet; m, multiplet). FAB-MS were recorded on Jeol SX 102 spectrometer using argon/xenon (6kV, 10mA) as the FAB gas. Glycerol or *m*-nitrobenzyl alcohol was used as matrix. Melting points of the compounds were recorded on Complab melting point apparatus and were uncorrected. All chemicals and reagents were obtained from Aldrich (USA), Spectrochem Pvt. Ltd. (India) and Lancater Pvt. Ltd (UK). Unless otherwise stated, room temperature was *ca.* 30 °C.

#### General procedure and characterization data

**General procedure for the preparation of  $\alpha$ - $\beta$  unsaturated esters (preparation of **3a** as representative):** A mixture of 37.7 g crude **2a** and 2 g of pTSA in benzene (300 mL) was refluxed on oil bath fitted with a condenser and Dean stark apparatus initially for 2 h till no more reactant left and then for an additional 1 h to isomerize  $\beta$ - $\gamma$  unsaturated ester to  $\alpha$ - $\beta$  unsaturated ester. Reaction mixture was cooled and washed with saturated  $\text{NaHCO}_3$  solution. Organic layer was decanted and aqueous layer was extracted with  $3 \times 50$  mL of ether, combined organic layer was dried over anhydrous  $\text{Na}_2\text{SO}_4$ , concentrated and purified by column chromatography over silica gel (60-120 mesh) using EtOAc:hexane (5:95) as eluant furnished 21.77 g (55 % yield) of product [**3a**] an oil. IR (neat,  $\text{cm}^{-1}$ ) 1628.7, 1713.8;  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ),  $\delta$  1.31 (t, 3H,  $J = 7.1$  Hz), 2.57 (d, 3H,  $J = 1.2$  Hz), 4.21 (q, 2H,  $J = 7.1$ Hz), 6.13 (d, 1H,  $J = 1.2$  Hz), 7.33-7.49 (m, 5H, Ar-H).

Compound **3b-e** were prepared by the same procedure.

**Compound 3b [3-*p*-tolyl-but-2-enoic acid ethyl ester]:** Yield 59 %, oil, IR (KBr,  $\text{cm}^{-1}$ ) 1628,1716.7;  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ) d 1.31 (t, 3H,  $J = 7$  Hz), 2.36 (s, 3H), 2.56 (d, 3H,  $J = 1$ Hz), 4.21 (q, 2H,  $J = 7$ Hz), 6.12 (d, 1H,  $J = 1$  Hz), 7.12-7.74 (m, 4H).

**Compound 3c [3-(4-methoxy-phenyl)-but-2-enoic acid ethyl ester]:** Yield 56 %, oil, IR (KBr,  $\text{cm}^{-1}$ ) 1605.2, 1706.2;  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ),  $\delta$  1.22 (t, 3H,  $J = 7$  Hz), 2.48 (d, 3H,  $J = 0.7$  Hz), 3.73 (s, 3H), 4.12 (q, 2H,  $J = 7$  Hz), 6.02 (d, 1H,  $J = 0.8$  Hz), 6.80 (d, 2H,  $J = 8.6$  Hz, Ar-H), 7.34-7.39 (d, 2H), (s, 1H).

**Compound 3d [3-(4-chloro-phenyl)-but-2-enoic acid ethyl ester]:** Yield 60 %, oil, IR (KBr,  $\text{cm}^{-1}$ ), 1629.7, 1712.7;  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ),  $\delta$  1.31 (t, 3H,  $J = 7$  Hz), 2.54 (d, 3H,  $J = 0.6$  Hz), 4.21 (q, 2H,  $J = 7$  Hz), 6.10 (d, 1H,  $J = 0.7$  Hz), 7.31-7.43 (m, 5H, Ar-H).

**Compound 3e [3-(4-fluoro-phenyl)-but-2-enoic acid ethyl ester]:** Yield 66 %, oil, IR (KBr,  $\text{cm}^{-1}$ ), 1631.7, 1712.7;  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ),  $\delta$  1.31 (t, 3H,  $J = 7.1$  Hz), 2.55 (d, 3H,  $J = 1$  Hz), 4.21 (q, 2H,  $J = 7.1$  Hz), 6.09 (d, 1H,  $J = 1$  Hz), 7.01-7.09 (m, 2H), 7.42-7.49 (m, 2H).

**General procedure for the preparation of allyl alcohol (preparation of 4a as representative):** To an ice cooled slurry of lithium aluminium hydride (6 g, 0.15 mol) in dry ether (300 mL), taken in a 1 L round bottom flask, kept at 0-10 °C, under nitrogen atmosphere with continuous stirring, 20 g (0.11 mol) of compound 3a was added *via* dropping funnel. The reaction mixture was stirred, till no more reactant was left. Reaction mixture was quenched by gradual addition of water, then finally with 10 % NaOH, till a sludge settled at the bottom. The ether layer was decanted and the sludge was washed with 3 × 50 mL of ether, combined organic layer was concentrated and purified by column chromatography over silica gel (60-120 mesh) using EtOAc:hexane (10:90) as eluant furnished 11.06 g (71 % yield) of product [4a] as oil. IR (Neat, cm<sup>-1</sup>) 1648.1, 3359.5; <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>), 2.06 (s, 3H), 2.37 (s, 1H, -OH, replaceable with D<sub>2</sub>O), 4.34 (d, 2H, *J* = 6.6 Hz), 5.95 (dt, 1H, *J* = 6.6 Hz, *J* = 1.2 Hz), 7.24-7.52 (m, 5H).

Compound 4b-4e were prepared by the same procedure.

**Compound 4b [3-*p*-tolyl-but-2-en-1-ol]:** Yield 73 %, oil, IR (KBr, cm<sup>-1</sup>) 1647.1, 3359.8; <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>), δ 1.45-1.46 (d, 1H, -OH replaceable with D<sub>2</sub>O), 2.06 (s, 3H), 2.34 (s, 3H), 4.35 (d, 2H, *J* = 6.7 Hz), 5.93 (t, 1H, *J* = 6.6 Hz), 7.08-7.33 (m, 4H, Ar-H).

**Compound 4c [3-(4-methoxy-phenyl)-but-2-en-1-ol]:** Yield 78 %, oil, IR (KBr, cm<sup>-1</sup>) 1604.8, 3345.4 (broad); <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>), δ 1.6-1.7 (s, 1H, -OH replaceable with D<sub>2</sub>O), 2.05 (s, 3H), 3.80 (s, 3H), 4.34 (d, 2H, *J* = 6.7 Hz), 5.91 (t, 1H, *J* = 6.7 Hz), 6.86 (dd, 2H, *J* = 6.7, 2 Hz), 7.35 (dd, 2H, *J* = 6.7, 2 Hz).

**Compound 4d [3-(4-chloro-phenyl)-but-2-en-1-ol]:** Yield 62 %, oil, IR (KBr, cm<sup>-1</sup>), 1646.2, 3337 (broad), <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>), δ 1.49 (s, 1H, -OH replaceable with D<sub>2</sub>O), 2.05 (s, 3H), 4.34-4.37 (d, 2H, *J* = 6.2 Hz), 5.95 (dt, 1H, *J* = 1 Hz, 7 Hz), 7.26-7.36 (m, 5H, Ar-H).

**Compound 4e [3-(4-fluoro-phenyl)-but-2-en-1-ol]:** Yield 78 %, oil, IR (KBr, cm<sup>-1</sup>), 1646.8, 3278.1 (broad); <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>), δ 1.49 (s, 1H, -OH replaceable with D<sub>2</sub>O), 2.05 (s, 3H), 4.35 (d, 2H *J* = 6.1 Hz), 5.92 (t, 1H, *J* = 6 Hz), 6.96-7.04 (m, 2H), 7.33-7.40 (m, 2H).

**General procedure for the preparation of admantane substituted spiro 1,2,4-trioxane (preparation of 5a as representative):** A solution of allyl alcohol 4a (9.5 g, 0.06 mol) methylene blue (5 mg) in acetonitrile (700 mL) taken in a double jacketed round bottom flask, maintained below 0-10 °C through ultra cryostat. Oxygen was bubbled into the reaction mixture and mixture was irradiated with visible light by means of tungsten-halogen lamp (500 W), till no more reactant was left in reaction mixture. Reaction mixture was poured in a 500 mL round bottom flask, 20 g of 2-admantanone, 2-4 drops of conc. HCl was added and reaction mixture stirred at room temperature till no more hydroperoxide was left. Reaction mixture was concentrated under reduce pressure and further purified by column chromatography over silica gel (60-120 mesh) using EtOAc:hexane (1:99) as eluant furnished 9.4 g (47 % yield) of product [7a] as oil. IR (KBr, cm<sup>-1</sup>) 1111.7, 1627; <sup>1</sup>H NMR (200 MHz,

CDCl<sub>3</sub>),  $\delta$  1.56-2.09 (m, 13H), 2.95 (s, 1H), 3.75 (dd, 1H,  $J = 11.8, 3$  Hz), 3.89-4.0 (m, 1H), 5.26 (dd, 1H,  $J = 10.3, 3$  Hz), 5.31 (s, 1H), 5.50 (s, 1H), 7.25-7.42 (m, 5H), FAB-MS (M+H) 313.

Compounds **5b-e** were prepared by the same procedure.

**Compound 5b:** Yield 40 %, oil, IR (KBr, cm<sup>-1</sup>), 1111.7, 1621.5; <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>)  $\delta$  1.56 (s, 3H), 1.59-2.34 (m, 13H), 2.9 (s, 1H), 3.78 (dd, 1H), 3.88-3.93 (m, 1H), 5.26-5.29 (m, 2H), 5.46 (s, 1H), 7.14 (d, 2H,  $J = 8$  Hz), 7.28 (d, 3H,  $J = 10$  Hz), FAB-MS (M+H), 327.

**Compound 5c:** Yield 42 %, oil, IR (KBr, cm<sup>-1</sup>), <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>),  $\delta$  1.57-2.09 (m, 13H), 2.95 (s, 1H), 3.79 (s, 3H), 3.71-4.0 (m, 2H), 5.21-5.26 (m, 2H), 5.41 (s, 1H), 6.85 (d, 2H,  $J = 8.7$  Hz, Ar-H), 7.33 (d, 2H,  $J = 8.7$  Hz, Ar-H). FAB-MS (M+H), 343.

**Compound 5d:** Yield 46 %, oil, IR (KBr, cm<sup>-1</sup>), 1596.4, 1093.3; <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>),  $\delta$  1.56-2.0 (m, 13H), 2.91 (s, 1H), 3.74 (dd, 1H,  $J = 11.8$  Hz, 3Hz), 3.89-4.00 (m, 1H), 5.19 (dd, 1H,  $J = 10.1$  Hz, 3 Hz), 5.33 (s, 1H), 5.49 (s, 1H), 7.26-7.32 (m, 4H, Ar-H), FAB-MS (M+H), 347.

**Compound 5e:** Yield 46 %, oil, IR (KBr, cm<sup>-1</sup>), 1637.2, 1111.9; <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>),  $\delta$  1.42-2.07 (m, 13H), 2.92 (s, 1H), 3.82 (dd, 1H,  $J = 7$  Hz, 1 Hz), 3.89-3.94 (m, 1H), 5.30 (dd, 1H,  $J = 7$  Hz, 1 Hz), 5.30 (s, 1H), 5.45 (s, 1H), 6.98-7.07 (m, 2H, Ar-H), 7.33-7.40 (m, 2H, Ar-H). FAB-MS (M+H), 332.

## RESULTS AND DISCUSSION

In this work, 5 simple 1,2,4-trioxanes were synthesized using readily available and simple starting material in good to moderate yield. Like semisynthetic artemisinin derivatives, many of these synthetic 1,2,4-trioxanes are quite stable and can serve as good lead compound for the development of new antimalarial compounds with promising antimalarial activity.

## ACKNOWLEDGEMENTS

The authors are grateful to AICTE for providing GATE scholarship and CDRI, Lucknow for providing spectral and analytical data.

## REFERENCES

1. W.H.O. Drug Information Bulletin, Vol. 13, p. 9 (1999).
2. Phytochemistry Section, Institute of Materia Medica, Chinese Academy of Medical Sciences, Summary of the Research of Chinese Traditional and Herbal Medicines, *Acta Pharm. Sinica*, **14**, 746 (1979).
3. X.X. Xu, J. Zhu, D.Z. Huang and W.S. Zhou, *Tetrahedron Lett.*, **32**, 5785 (1991).
4. C. Jaquet, H.R. Stohler, J. Chollet and W. Peters, *Trop. Med. Parasitol.*, **45**, 266 (1994).
5. W. Hofheinz, H. Burgin, E. Gocke, C. Jaquet, R. Masciadri, G. Schmid and H. Stohler, *Trop. Med. Parasitol.*, **45**, 261 (1994).
6. (a) C.W. Jefford, D. Jaggi, J. Boukouvalas and S. Kohmoto, *J. Am. Chem. Soc.*, **105**, 6498 (1983); (b) J.A. Kepler, A. Philip, Y.W. Lee, M.C. Morey and F.I. Carroll, *J. Med. Chem.*, **31**, 713 (1988); (c) T. Fujisakum, M. Miura, M. Nojima and S. Kasabayashi, *J. Chem. Soc. Perkin Trans. I*,

- 1031 (1989); (d) M.A. Avery, C. Jennings-White and W.K.M. Chong, *J. Org. Chem.*, **54**, 1792 (1989); (e) A.J. Bloodworth and A. Shah, *J. Chem. Soc. Chem. Commun.*, 947 (1991); (f) G.H. Posner, C.H. Oh and W.K. Milhous, *Tetrahedron Lett.*, **32**, 4235 (1991); (g) W.H. Bunnelle, T.A. Isbell, C.L. Barnes and S. Qualls, *J. Am. Chem. Soc.*, **113**, 8168 (1991); (h) A.J. Bloodworth and K.A. Johnson, *Tetrahedron Lett.*, **35**, 8057 (1994); (i) P.M. O'Neill, M. Pugh, J. Davies, S.A. Ward and B.K. Park, *Tetrahedron Lett.*, **42**, 4569 (2001); (j) P.M. O'Neill, A. Mukhtar, S.A. Ward, J.F. Bickley, J. Davies, M.D. Bachi and P.A. Stocks, *Org. Lett.*, **6**, 3035 (2004).
7. (a) C. Singh, *Tetrahedron Lett.*, **31**, 6901 (1990); (b) C. Singh, D. Misra, G. Saxena and S. Chandra, *Bioorg. Med. Chem. Lett.*, **2**, 497 (1992); (c) C. Singh, D. Misra, G. Saxena and S. Chandra, *Bioorg. Med. Chem. Lett.*, **5**, 1913 (1995); (d) C. Singh, N. Gupta and S.K. Puri, *Bioorg. Med. Chem. Lett.*, **12**, 1913 (2002); (e) C. Singh, H. Malik and S.K. Puri, *Bioorg. Med. Chem. Lett.*, **12**, 1177 (2004); (f) C. Singh, N.C. Srivastav and S.K. Puri, *Bioorg. Med. Chem.*, **12**, 5745 (2004); (g) C. Singh, H. Malik and S.K. Puri, *Bioorg. Med. Chem.*, **14**, 459 (2004); (h) C. Singh, N. Gupta and S.K. Puri, *Bioorg. Med. Chem.*, **12**, 5553 (2004); (i) C. Singh, N. Gupta, S.K. Puri, *Tetrahedron Lett.*, **46**, 205 (2005); (j) C. Singh, H. Malik and S.K. Puri, *J. Med. Chem.*, **49**, 2794 (2006); (k) C. Singh, R. Kanchan, D. Srivastava and S.K. Puri, *Bioorg. Med. Chem. Lett.*, **16**, 584 (2006); (l) C. Singh, R. Kanchan, U. Sharma and S.K. Puri, *J. Med. Chem.*, **50**, 521 (2007).
8. (a) W. Adam and N. Duran, *J. Chem. Soc. Chem. Commun.*, 798 (1972); (b) P.H. Dussault, T.K. Trullinger and F. Noor-e-Ain, *Org. Lett.*, **4**, 4591 (2002).
9. C.H. Oh and J.H. Kang, *Tetrahedron Lett.*, **39**, 2771 (1998).
10. (a) P.H. Dussault and D.R. Davies, *Tetrahedron Lett.*, **37**, 463 (1996); (b) Y. Ushigoe, Y. Kano and M. Nojima, *J. Chem. Soc. Perkin Trans. I*, 5 (1997); (c) Y. Ushigoe, Y. Torao, A. Masuyama and M. Nojima, *J. Org. Chem.*, **62**, 4949 (1997); (d) Y. Ushigoe, A. Masuyama, M. Nojima and K.J. McCullough, *Tetrahedron Lett.*, **38**, 8753 (1997); (e) A. Ahmed and P.H. Dussault, *Org. Lett.*, **6**, 3609 (2004).
11. R. Amewu, A.V. Stachulski, N.G. Berry, S.A. Ward, J. Davies, G. Labat, J.F. Rossignol and P.M. O'Neill, *Bioorg. Med. Chem. Lett.*, **16**, 6124 (2006).
12. C. Singh, S. Pandey, G. Saxena, N. Srivastava and M. Sharma, *J. Org. Chem.*, **71**, 9057 (2006).

(Received: 24 May 2008;

Accepted: 10 February 2009)

AJC-7223